Skip to content
lifestyle.thepointnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vascarta Inc
Vascarta Outlines VAS-101’s (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer
August 25, 2026
Vascarta Outlines Proposed Mechanistic Link Between VAS-101’s (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease
August 20, 2026
Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins
August 19, 2026
Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
June 24, 2026
Vascarta Announces Addition of Richard Serbin to Leadership Team
June 9, 2026